Swine streptococcosis nanoparticle vaccine and application thereof
By combining Streptococcus suis antigen protein with 2-methylimidazole and zinc acetate to form a metal organic framework nanoparticle and spore-complex microsphere vaccine, the problem of limited protection effect of existing Streptococcus suis vaccine is solved and efficient Immune protection and stability simplifies the preparation process and reduces costs.
Patent Information
- Application Number
- CN202411277271.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-12
- Publication Date
- 2024-11-08
AI Technical Summary
The existing vaccine for streptococcal disease is limited in its protective effect, and due to the high serotype diversity and variability, it is difficult to provide long-term immune protection.
Using metal-organic framework nanoparticles and spore composite nanomicrosphere vaccine, the streptococcal suis antigen protein is combined with 2-methylimidazole and zinc acetate to form stable nanoparticles or spore composite microspheres, and the particle diameter is detected by dynamic light scattering. and potential to ensure the uniformity and dispersion of the vaccine, and conduct an evaluation of the effectiveness of immune protection.
It achieves an immune protection effect comparable to that of commercial vaccines, provides a long-term immune response, improves the stability and stress resistance of the antigen, simplifies the preparation process, reduces costs, and increases the loading and immune protection of the antigen. Effect.
Smart Images

Figure CN118903398A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedicine, and specifically relates to a nanoparticle vaccine for swine streptococcal disease and an application thereof. Background Art
[0002] Streptococcus suis is a zoonotic pathogen prevalent worldwide and one of the most serious bacterial pathogens that harm the pig industry. Infection with Streptococcus suis can cause diseases such as meningitis, arthritis and sepsis in pigs. The high rate of infection in pigs causes huge economic losses to the pig industry. At present, vaccination is an important means to prevent Streptococcus suis infection. Although there are commercial vaccines for Streptococcus suis, the protective effect of the vaccine needs to be further improved due to the numerous serotypes of Streptococcus suis and rapid mutation. Therefore, it is of great significance to develop a new vaccine for Streptococcus suis with good protection, high safety and strong cross protection.
[0003] Nanoparticle vaccines have become a hot topic in the research of new vaccines in recent years. Nanoparticles (NPs) are small in size, with a particle size range of usually between 10-1000nm. By regulating the surface potential of the carrier, they can interact with the biological membrane to achieve targeted delivery of antigens. Nanoparticles are small in size and large in specific surface area. They not only have a high antigen loading rate, but also can promote the efficient uptake of antigens by antigen-presenting cells, thereby triggering a stronger immune response in the body. Therefore, nanoparticles have both the vaccine delivery effect of antigen substances and the vaccine adjuvant effect of enhancing the body's immune response. Nanoparticles can be divided into protein nanoparticles, lipid nanoparticles, organic polymer nanoparticles, and inorganic nanoparticles.
[0004] Metal-organic frameworks (MOFs) are an emerging type of porous nanomaterial, which is self-assembled from inorganic metal centers (such as metal ions or metal clusters) and organic ligands. They have the characteristics of simple synthesis, high specific surface area, controllable pore structure and high stability. They have been widely used in drug delivery, tumor immunity and vaccine design. They have good biocompatibility and are an ideal antigen protection and delivery carrier. Summary of the invention
[0005] One purpose of the present invention is to construct a nanoparticle vaccine for swine streptococcal disease, in particular a metal organic framework nanoparticle vaccine for swine streptococcal disease, and evaluate its immune protection effect.
[0006] In order to achieve the above object, the technical solution of the present invention is as follows:
[0007] (1) The antigen protein 1 gene and antigen protein 2 gene of Streptococcus suis were cloned into the pET28a expression plasmid. The two recombinant expression vector plasmids were transformed into the competent cells of Escherichia coli ClearColi BL21, and then induced with 0.8 mol / L IPTG for 8 h at 37°C, and then purified by Ni column to obtain antigen protein 1 (sequence shown in SEQ NO.1) and antigen protein 2 (sequence shown in SEQ NO.2).
[0008] (2) The preparation process of nanoparticle vaccine Vaccine 1 is as follows: antigen protein 1 and antigen protein 2 are mixed with 2-methylimidazole solution respectively, and then zinc acetate solution is added and stirred at 4°C for 24 hours. After that, the mixture is washed three times with ultrapure water and the precipitated particles are collected by centrifugation to obtain two nanoparticles. The two nanoparticles are mixed in a 1:1 ratio to obtain Vaccine 1, in which the concentration of the two antigen proteins is 500 mg / mL.
[0009] (3) The preparation process of the nanoparticle vaccine Vaccine2 is as follows: Bacillus subtilis WB800N is cultured in DSM medium to form spores. After the culture is completed, the bacteria are collected by centrifugation, and then the vegetative cells are lysed with lysozyme. After washing, the spores of Bacillus subtilis are obtained. The purified spores of Bacillus subtilis are soaked in a 2-methylimidazole solution, and then the spores are resuspended with a 2-methylimidazole solution, and two kinds of Streptococcus suis antigen proteins 1 and antigen protein 2 are added respectively, and then a zinc acetate solution is added, and stirred at 4°C for 24 hours. After that, it is washed three times with ultrapure water. The precipitated particles are collected by centrifugation to obtain two kinds of spore composite nanospheres. The two kinds of spore composite nanospheres are mixed in a ratio of 1:1 to obtain the nanoparticle vaccine Vaccine2, wherein the concentrations of the two antigen proteins are 500 mg / mL respectively.
[0010] (4) Dynamic light scattering (DLS) was used to detect and analyze the particle size distribution and potential of the two types of spore composite nanospheres. It was found that the particle size of each group of samples was uniform and the dispersion was good, indicating that the preparation method of the present invention is reliable and the quality of the prepared samples is controllable.
[0011] (5) Four-week-old KM mice were divided into five groups. The first group was a negative control group. The second group was immunized with a homemade Streptococcus suis subunit vaccine (i.e., purified Streptococcus suis antigen protein 1 and antigen protein 2 emulsified with Freund's adjuvant in a ratio of 1:1). The third group was immunized with Vaccine 1, the fourth group was immunized with Vaccine 2, and the fifth group was immunized with a commercial Streptococcus suis subunit vaccine. Booster immunization was performed 14 days after the first immunization. Ten days after the second immunization, mice in each group were challenged with Streptococcus suis. The immune protection effect of the vaccine was evaluated by mouse survival rate, clinical symptoms, tissue bacterial load, antibody level detection and other indicators. The results showed that after challenge with a lethal dose of Streptococcus suis, the survival rate of mice in the non-immunized control group was only 20%, while the homemade subunit vaccine, metal organic framework vaccine, spore-metal organic framework vaccine and commercial subunit vaccine could provide 100%, 100%, 100% and 75% protection rates, respectively. The results of tissue bacterial load experiments showed that the bacterial load in the heart, liver, spleen and kidney of mice in the immune vaccine 1, immune vaccine 1 and commercialized Streptococcus suis subunit vaccine groups was lower than that in the negative control group. In summary, the metal organic framework vaccine and spore-metal organic framework vaccine for Streptococcus suis disease constructed in this study can provide immune efficacy comparable to that of commercialized subunit vaccines.
[0012] Compared with the prior art, the beneficial effects of this solution are:
[0013] (1) The present invention provides composite nanoparticle microspheres based on spores, which can provide a stable microenvironment for antigen protein molecules of Streptococcus suis virus, increase the chemical stability of antigen protein molecules, and combine the delivery effect of vaccine antigens or proteins with the sustained release effect, thereby inducing a long-lasting immune response and building an effective immune defense system. Spores are a material with strong stress resistance, high stability, easy preparation, transportation and storage, which has a protective effect on antigens, can increase the concentration of antigens on the mucosal surface, and improve the efficiency of antigen presentation. Due to the excellent stress resistance of spores, the proteins displayed in this way have good stability, which is convenient for their transportation, storage and application.
[0014] (2) The spores introduced in the present invention are used to prepare spore composite nanosphere vaccines. The introduction of spores can increase the loading amount of antigen proteins and play the role of vaccine adjuvants. The spores can stimulate the body's mucosal immunity, allowing the vaccine to exert a more comprehensive immune protection effect, and the negative charge carried by the spores is beneficial to the stability of the vaccine.
[0015] (3) The preparation method of the vaccine proposed in the present invention is simple and does not require complicated genetic manipulation. It only requires prokaryotic expression and purification of the required antigen, and the spore-metal organic framework vector vaccine is prepared by a one-step method. Therefore, a new vector vaccine for swine streptococcal disease loaded with different antigens can be quickly obtained, which is conducive to the development of multivalent vaccines.
[0016] (4) The vaccine proposed in the present invention does not require emulsification or Freund's adjuvant during preparation. The preparation cost of the spores and ZIF-8 used is low, lower than that of Freund's adjuvant. During the injection process, it was found that the subunit vaccine emulsified with Freund's adjuvant was difficult to inject, while the vaccine solution was easier to inject. In addition, the one-step vaccine preparation method effectively reduces the loss of antigen protein, which has certain economic benefits. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 It is the SDS-PAGE picture of the purified antigen protein 1 (M: 180 kDa protein marker, 3-5: purified antigen protein 1).
[0018] Figure 2 It is the SDS-PAGE picture of the purified antigen protein 2 (M: 180 kDa protein marker, 4-6: purified antigen protein 2).
[0019] Figure 3 It is an SDS-PAGE detection diagram of nanoparticles (wherein, strip 1 is nanoparticle 1 of Example 2, strip 2 is nanoparticle 2 of Example 2, strip 3 is spore composite nanosphere 1 of Example 3, and strip 4 is spore composite nanosphere 2 of Example 3).
[0020] Figure 4 It is a graph showing the results of nanoparticle size measurement (wherein 1 is spore, 2 is ZIF8, 3 is nanoparticle 1 of Example 2, 4 is nanoparticle 2 of Example 2, 5 is spore composite nano-microsphere 1 of Example 3, and 6 is spore composite nano-microsphere 2 of Example 3).
[0021] Figure 5 It is a graph showing the results of the zeta potential measurement of nanoparticles (wherein 1 is spores, 2 is ZIF8, 3 is nanoparticle 1 of Example 2, 4 is nanoparticle 2 of Example 2, 5 is spore composite nanosphere 1 of Example 3, and 6 is spore composite nanosphere 2 of Example 3).
[0022] Figure 6 This is the survival curve of mice after virus attack (Group 1: negative non-immunized group; Group 2: homemade subunit vaccine group; Group 3: Vaccine 1 group; Group 4: Vaccine 2 group; Group 5: commercialized Streptococcus suis subunit vaccine group; * indicates, P<0.05).
[0023] Figure 7The figure shows the bacterial load in mouse organs after infection (Group 1: negative non-immunized group; Group 2: homemade subunit vaccine group; Group 3: Vaccine1 group; Group 4: Vaccine2 group; Group 5: commercialized Streptococcus suis subunit vaccine group. * indicates P<0.05, * indicates P<0.05, ** indicates P<0.01).
[0024] Figure 8 It is the specific IgG level against antigen protein 1 and antigen protein 2 in mouse serum (Group 1: negative non-immunized group; Group 2: homemade subunit vaccine group; Group 3: Vaccine 1 group; Group 4: Vaccine 2 group; Group 5: commercialized Streptococcus suis subunit vaccine group. * represents P < 0.05, ** represents P < 0.01). DETAILED DESCRIPTION
[0025] The present invention is described below with reference to specific examples. It will be appreciated by those skilled in the art that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention in any way.
[0026] Example 1 Expression and purification of antigenic protein
[0027] (1) The pET28a plasmid was double-digested with restriction endonucleases BamHI and NdeⅠ, subjected to 1% agarose gel electrophoresis, and a linearized vector fragment was recovered using a DNA recovery kit;
[0028] (2) Primers were designed using the genome of Streptococcus suis SC19 (Gene Bank No. NZ_CP020863.1) as a template, and the following primers 1 and 2 were used to amplify the gene fragment of antigen protein 1 (HP0197 protein), and primers 3 and 4 were used to amplify the gene fragment of antigen protein 2 (HP1036 protein):
[0029] Primer 1 (SEQ ID NO: 3): 5'-actttaagaaggagatatacatggaaactgcaaataaaaaattc-3',
[0030] Primer 2 (SEQ ID NO: 4): 5'-tggtggtggtggtggatttgatctttagattttttgtttata-3',
[0031] Primer 3 (SEQ ID NO: 5): 5'-aagaaggagatatacatgaaaagatctttaggtgaaaag-3',
[0032] Primer 4 (SEQ ID NO: 6): 5'-tggtggtggtggtgtctcagtaacattgaagacattttgta-3'.
[0033] (3) The linearized pET28a vector fragment was connected to the antigen protein 1 gene fragment and the antigen protein 2 gene fragment respectively using homologous recombinase, and then the ligation products were transformed into Escherichia coli DH5α competent cells and cultured at 37°C overnight. Colony PCR amplification was performed using universal primers for vector pET28a to screen and identify positive clones. The pET28a-1 plasmid and the pET28a-2 plasmid were extracted using a plasmid extraction kit, and DNA sequencing was performed to identify the recombinant plasmids pET28a-1 and pET28a-2.
[0034] (4) The recombinant plasmids pET28a-1 and pET28a-2 were transformed into Escherichia coli ClearColi (DE3), respectively. Pick a single colony, inoculate it into 10 mL LB medium, and shake it at 37°C, 180 r overnight. Inoculate it into 800 mL LB medium at 1:100, and induce it with 0.8 mol / L IPTG at 37°C overnight. Collect the bacteria by centrifugation at 4°C, 10000 r / min for 10 min, discard the supernatant and resuspend it with 40 mL PBS, and crush it under high pressure until the bacterial liquid is clear. Centrifuge at 4°C, 10000 r / min for 30 min, and filter the supernatant with a 0.22 μm filter. Apply the supernatant to the nickel column at a flow rate of 14 r / min for 2 h. Connect the nickel column to the protein purification cabinet for elution. Take the eluted sample for sample preparation, run SDS-PAGE gel, and stain with Coomassie Brilliant Blue. Ultrafiltration concentration bands are pure target antigen protein 1 and antigen protein 2 (such as Figure 1 and 2 The protein concentration was determined by BCA kit. The sizes of antigen protein 1 (HP0197 protein) and antigen protein 2 (HP1036 protein) were 55.0 KDa and 50.8 KDa, respectively. The amino acid sequences of antigen protein 1 (HP0197 protein) and antigen protein 2 (HP1036 protein) are shown in SEQ NO.1 and SEQ NO.2, respectively.
[0035] Example 2 Preparation of Nanoparticle Vaccine 1
[0036] (1) Prepare 1 mL of 1.0 mg / mL antigen protein 1 (HP0197 protein) and 1 mL of 1.20 mol / L 2-methylimidazole solution, then add 1 mL of 0.6 mol / L zinc acetate solution, and stir at 4°C for 24 h. Wash three times with ultrapure water. Collect the precipitated particles by centrifugation to obtain two nanoparticles, namely, nanoparticle 1 based on antigen protein 1 (HP0197 protein) and nanoparticle 2 based on antigen protein 2 (HP1036 protein).
[0037] (2) Take 30 μL of each of the two nanoparticles and mix them with 10 μL of 4X protein loading buffer to prepare samples, and perform SDS-PAGE and Western Blot analysis to determine whether the antigen protein is adsorbed on the nanoparticles (e.g. Figure 3 middle strip 1 and strip 2).
[0038] (3) Dynamic light scattering (DLS) was used to measure the particle size and potential of the samples to determine the particle size and potential of the nanoparticles (e.g. Figure 4 3 and 4 in, such as Figure 5 3 and 4), in this embodiment, the particle size of HP0197@ZIF-8 is about 3000nm, and the particle size of HP1036@ZIF-8 is about 4500nm. The particle sizes of these two nanoparticles are relatively large. The main reason is that the imidazole and protein on the surface of ZIF-8 microspheres are easy to form polymers, which increases the particle size of the nanoparticles.
[0039] (4) The two nanoparticles obtained are mixed in a ratio of 1:1, and the concentrations of antigen protein 1 and antigen protein 2 are both 500 mg / ml, thereby obtaining the nanoparticle vaccine Vaccine 1.
[0040] Example 3 Preparation of Nanoparticle Vaccine 2
[0041] (1) Pick a single colony of Bacillus subtilis WB800N and inoculate it into 5 mL LB medium and culture it at 37°C overnight. Transfer it to 500 mL DSM medium at 1:50 the next day and culture it at 37°C, 180 r / min, on a shaking table for 2 days. After the culture is completed, centrifuge at 10,000 r / min for 10 min to collect the bacteria. Resuspend the bacteria in 20 mL sterile water, add lysozyme to a final concentration of 2 mg / mL, and incubate at 37°C for 30 min. Centrifuge at 10,000 r / min for 10 min to collect the bacteria, and wash the bacterial precipitate three times with sterile water to obtain the purified spores.
[0042] (2) Soak the wild-type WB800N spores in a 1.2 mol / L 2-methylimidazole solution for 2 h to saturate the organic ligands adsorbed on the surface. Resuspend the spores with a 1.2 mol / L 2-methylimidazole solution, wash away the spores not bound to 2-methylimidazole, add 1 mL of 0.5 mg / mL antigen protein 1 and antigen protein 2 solution, and then add 1 mL of 0.6 mol / L zinc acetate solution, and stir at 4 ° C for 24 h. Wash three times with ultrapure water. Collect the precipitated particles by centrifugation, which are the two spore composite nanospheres.
[0043] (3) Take 30 μL of spore composite nanospheres and 10 μL of 4X protein loading buffer and mix them to prepare samples, and perform SDS-PAGE and Western Blot analysis to determine whether the antigen protein is adsorbed on the spore composite nanospheres (such as Figure 3 middle strip 3 and strip 4).
[0044] (4) Dynamic light scattering (DLS) was used to measure the particle size and potential of the sample to determine the particle size and potential of the spore composite nanospheres (e.g. Figure 4 5 and 6, such as Figure 5 5, 6).
[0045] (5) The two spore composite nanospheres were mixed in a ratio of 1:1, and the concentrations of antigen protein 1 and antigen protein 2 were both 500 mg / ml, thereby obtaining the nanoparticle vaccine Vaccine 2.
[0046] The advantages of the vaccines prepared in Examples 3 and 4 are that they are easy to prepare, do not require emulsification, and are less expensive than Freund's adjuvant. During the injection process, it was found that the subunit vaccine emulsified with Freund's adjuvant was difficult to inject, while the vaccine solution was easier to inject.
[0047] Example 4 Evaluation of vaccine immune protection effect
[0048] (1) Four-week-old KM mice were divided into five groups. The first group was a negative control group, the second group was immunized with a homemade Streptococcus suis subunit vaccine (i.e., purified Streptococcus suis antigen protein 1 and antigen protein 2 emulsified with Freund's adjuvant in a ratio of 1:1), the third group was immunized with Vaccine 1, the fourth group was immunized with Vaccine 2, and the fifth group was immunized with a commercial Streptococcus suis subunit vaccine. A booster immunization was performed 14 days after the first immunization. The results showed that there were no obvious clinical symptoms in the mice in each group after the first and second immunizations, and the appetite, spirit and movement of the mice were normal, and there was no death.
[0049] (2) On the 24th day after the first immunization, 5 mice were randomly selected from each group and challenged with a lethal dose of the virulent strain of Streptococcus suis SC19 by intraperitoneal inoculation. The mice were observed for one week, and the clinical symptoms and deaths of the mice after the challenge were recorded. The results showed that after the challenge with a lethal dose of Streptococcus suis SC19, the survival rate of the mice in the first group (negative non-immunized group) was only 20%, while the survival rates of the homemade second group (homemade subunit vaccine group), the third group (Vaccine 1 group), the fourth group (Vaccine 2 group), and the fifth group (commercial Streptococcus suis subunit vaccine group) were 100%, 100%, 100% and 80%, respectively (as shown in Figure 2). Figure 6 ). The results show that the two nanoparticle vaccines of the present invention can provide an immune protection effect comparable to that of commercial vaccines.
[0050] (3) On the 24th day after the first immunization, 10 mice were randomly selected from each group and challenged with a sublethal dose of the virulent strain of Streptococcus suis SC19 by intraperitoneal inoculation. During this period, 5 mice were killed at 12 and 24 hours after the challenge, and the heart, liver, spleen and kidney were removed to calculate the bacterial load in tissues and organs. The results showed that after the challenge with a lethal dose of Streptococcus suis SC19, the survival rate of mice in the first group (negative non-immunized group) was only 20%, while the bacterial load in the heart, liver, spleen and kidney of the mice in the second group (homemade subunit vaccine group), the third group (Vaccine1 group), the fourth group (Vaccine2 group) and the fifth group (commercialized Streptococcus suis subunit vaccine group) were lower than those in the negative control group (such as Figure 7 ).
[0051] (4) Blood was collected from the retro-orbital venous plexus of mice on days 6, 13, 20, 27, and 34 after the first immunization. The blood was collected in a 1.5 mL sterile centrifuge tube and allowed to stand at 37°C for 1 hour. The blood was then placed at 4°C overnight and centrifuged at 1000 r / min for 15 minutes. The upper serum was collected and packaged, and the antibody levels against antigen proteins 1 and 2 in the serum were determined using the indirect ELISA method. The results showed that the third group Vaccine 1 was able to induce the production of specific antibody levels comparable to those of commercial vaccines, while the fourth group Vaccine 2 was able to induce mice to produce higher levels of IgG antibodies than those immunized with commercial subunit vaccines (e.g., Figure 8 ).
Claims
1. A nanoparticle vaccine for swine streptococcal disease, characterized in that: The vaccine includes spores and antigens adsorbed on the surface of the spores by an organic solvent, wherein the surface of the antigen is encapsulated with a layer of metal organic framework structure, and the antigen contains the amino acid sequence of Streptococcus suis SC19 antigen protein 1 as shown in SEQ NO.1 and the amino acid sequence of Streptococcus suis SC19 antigen protein 2 as shown in SEQ NO.2, and the concentration ratio of antigen protein 1 to antigen protein 2 is 1:
1.
2. The vaccine according to claim 1, characterized in that The spores are formed by Bacillus subtilis WB800N.
3. The vaccine according to claim 1, characterized in that The metal organic framework structure is a nanocrystalline material ZIF-8.
4. The method for preparing the nanoparticle vaccine for swine streptococcal disease according to any one of claims 1 to 3, characterized in that: The following steps are involved: Step (1) purifying the spores formed by Bacillus subtilis and immersing them in an organic solvent solution to obtain a mixed solution in which the spore surface is saturated with the organic solvent; Step (2) then adding an organic solvent to the mixed solution of step (1) again to resuspend the spores, then adding a solution of antigen protein 1 and antigen protein 2 of Streptococcus suis SC19, and then adding a solution of a zinc ion compound, and stirring at low temperature to obtain a suspension containing particles; Step (3) The suspension in step (2) is fully washed and the precipitated particles are collected by centrifugation to obtain a vaccine containing two kinds of spore composite nano-microspheres. The two microspheres are mixed in a ratio of 1:1 to prepare the spore composite nano-microsphere vaccine.
5. The preparation method according to claim 4, characterized in that: The organic solvent in step (1) and step (2) is a methylimidazole precursor.
6. The preparation method according to claim 5, characterized in that: The methylimidazole precursor is 2-methylimidazole, and the concentration of 2-methylimidazole in step (1) and step (2) is 1.2 mol / L.
7. The preparation method according to claim 5, characterized in that: The zinc ion compound in step (2) is zinc acetate, zinc nitrate, or zinc oxide, and the molar ratio of the methylimidazole precursor to the zinc ion in the zinc ion compound is 2:
1.
8. The preparation method according to claim 4, characterized in that: The concentrations of the two antigen proteins in the spore composite nanosphere vaccine obtained in step (3) are both 500 mg / mL.
9. The nanoparticle vaccine for swine streptococcal disease as claimed in any one of claims 1 to 3, used in active immunization drugs for swine streptococcal disease.
Citation Information
Cited By
Yeast bionic vaccine based on metal organic framework ZIF-8 as well as construction method and application of yeast bionic vaccine
CN119454640A
